 The PI-3K Act pathway is a key regulator of cell growth and survival, playing a critical role in many biological processes such as metabolism, proliferation, and apoptosis. A barrent activation of this pathway has been observed in numerous types of cancer, making it an attractive target for anti-cancer drugs. Several inhibitors targeting the PI-3K Act pathway have been developed, but their efficacy is limited due to the development of resistance. Combinations of these inhibitors with other cancer treatments may be more effective in treating cancer. This article was authored by Yang He, Miao Miao Sun, Guo Keng Zhong, and others.